| Drug General Information |
| Drug ID |
D05ZRR
|
| Former ID |
DNC008477
|
| Drug Name |
9-(3-aminobenzyl)-6-(furan-2-yl)-9H-purin-2-amine
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C16H14N6O
|
| Canonical SMILES |
C1=CC(=CC(=C1)N)CN2C=NC3=C(N=C(N=C32)N)C4=CC=CO4
|
| InChI |
1S/C16H14N6O/c17-11-4-1-3-10(7-11)8-22-9-19-14-13(12-5-2-6-23-12)20-16(18)21-15(14)22/h1-7,9H,8,17H2,(H2,18,20,21)
|
| InChIKey |
XBESCJVITPKCJA-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
Adenosine A2a receptor |
Target Info |
Inhibitor |
[1]
|
|---|
| Adenosine A1 receptor |
Target Info |
Inhibitor |
[1]
|
|
KEGG Pathway
|
Rap1 signaling pathway
|
|
Calcium signaling pathway
|
|
cAMP signaling pathway
|
|
Neuroactive ligand-receptor interaction
|
|
Vascular smooth muscle contraction
|
|
Parkinson's disease
|
|
Alcoholismhsa04022:cGMP-PKG signaling pathway
|
|
Sphingolipid signaling pathway
|
|
Morphine addiction
|
|
NetPath Pathway
|
TCR Signaling Pathway
|
|
RANKL Signaling Pathway
|
|
PANTHER Pathway
|
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
|
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
|
|
Pathway Interaction Database
|
HIF-2-alpha transcription factor network
|
|
PathWhiz Pathway
|
Intracellular Signalling Through Adenosine Receptor A2a and Adenosine
|
|
Reactome
|
NGF-independant TRKA activation
|
|
Adenosine P1 receptors
|
|
G alpha (s) signalling events
|
|
Surfactant metabolismR-HSA-417973:Adenosine P1 receptors
|
|
G alpha (i) signalling events
|
|
WikiPathways
|
Nucleotide GPCRs
|
|
Monoamine Transport
|
|
GPCRs, Class A Rhodopsin-like
|
|
NGF signalling via TRKA from the plasma membrane
|
|
GPCR ligand binding
|
|
GPCR downstream signaling
|
|
GPCRs, OtherWP80:Nucleotide GPCRs
|
| References |
| REF 1 | Bioorg Med Chem Lett. 2008 May 1;18(9):2924-9. Epub 2008 Mar 30.Antagonists of the human adenosine A2A receptor. Part 3: Design and synthesis of pyrazolo[3,4-d]pyrimidines, pyrrolo[2,3-d]pyrimidinesand 6-arylpurines. |
|---|
